Listed

Pfizer Inc: Form 10-Q for the period ended Oct 2, 2022

Filed with the SEC on Nov 9, 2022 and accepted by EDGAR at Nov 9, 2022, 16:05 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-10-02. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-07-04 to 2022-10-02$22.64bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2022-01-01 to 2022-10-02$76.04bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2022-07-04 to 2022-10-02$6.06bnus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2022-01-01 to 2022-10-02$24.70bnus-gaap:CostOfGoodsAndServicesSold
Selling, general and administrative3 months2022-07-04 to 2022-10-02$3.39bnus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2022-01-01 to 2022-10-02$9.03bnus-gaap:SellingGeneralAndAdministrativeExpense
Interest expense3 months2022-07-04 to 2022-10-02$311.0mus-gaap:InterestExpense
Interest expense9 months2022-01-01 to 2022-10-02$925.0mus-gaap:InterestExpense
Income tax3 months2022-07-04 to 2022-10-02$356.0mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2022-01-01 to 2022-10-02$3.10bnus-gaap:IncomeTaxExpenseBenefit
Net income3 months2022-07-04 to 2022-10-02$8.61bnus-gaap:NetIncomeLoss
Net income9 months2022-01-01 to 2022-10-02$26.38bnus-gaap:NetIncomeLoss
Diluted EPS3 months2022-07-04 to 2022-10-02$1.51us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2022-01-01 to 2022-10-02$4.60us-gaap:EarningsPerShareDiluted
Basic EPS3 months2022-07-04 to 2022-10-02$1.54us-gaap:EarningsPerShareBasic
Basic EPS9 months2022-01-01 to 2022-10-02$4.71us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2022-07-04 to 2022-10-025,718,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2022-01-01 to 2022-10-025,729,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2022-01-01 to 2022-10-02$20.68bnus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2022-01-01 to 2022-10-02$2.23bnus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases9 months2022-01-01 to 2022-10-02$2.00bnus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2022-10-02$1.30bnus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-10-02$70.40bnus-gaap:AssetsCurrent
Total assetsAt period end2022-10-02$195.35bnus-gaap:Assets
Current liabilitiesAt period end2022-10-02$44.31bnus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-10-02$102.46bnus-gaap:Liabilities
Long-term debtAt period end2022-10-02$32.63bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2022-10-02$2.57bnus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2022-10-02$92.63bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000078003-22-000101. Last ingested by Listed: Nov 12, 2026, 18:08 ET. Listed shows no prices and gives no investment advice.